Skip to main content
. 2014 Aug 13;19(8):12150–12172. doi: 10.3390/molecules190812150

Figure 6.

Figure 6

Inhibitory effect of EGCG on VEGF-induced proliferation and vascular permeability by HRMECs. (A) HRMECs were treated with 10 ng/mL VEGF or 1–50 μM EGCG for 72 h. Cell viability was assessed by MTT assay. The results are expressed as percentage of control and are presented by mean ± SD (n = 9). *, p < 0.01 vs. VEGF and EGCG untreated; #, p < 0.01 vs. VEGF only; (B) HRMECs were treated with 10 ng/mL VEGF or 1–50 μM EGCG for 72 h. Permeability was analyzed by measuring the fluorescence of FITC-labeled dextran across the monolayer cultured HRMECs. The results are expressed as fold induction of control and are presented by mean ± SD (n = 9). *, p < 0.01 vs. VEGF and EGCG untreated; #, p < 0.01 vs. VEGF only.